Russian Journal of Allergy最新文献

{"title":"Preliminary results of a non-interventional single-center study evaluating the efficacy of long-term use of lanadelumab in routine clinical practice in the Russian Federation","authors":"E. Latysheva, I. A. Manto, L. V. Aleshina, E. Bobrikova, E. Viktorova, E. Gracheva, D. V. Demina, D. Fomina, A. Shcherbina, T. Latysheva","doi":"10.36691/rja5493","DOIUrl":"https://doi.org/10.36691/rja5493","url":null,"abstract":"BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency is a rare disease caused by a deficiency and/or a decrease in the functional activity of the C1 inhibitor. The primary symptom of this condition is recurrent angioedema of various localizations. According to the modern concept of treatment, the therapy aims to stop emerging angioedema and prevent death as well as achieve complete control of the disease and a high quality of life. Lanadelumab is a modern medicine developed and used to prevent attacks in patients with hereditary angioedema aged 12 years. \u0000AIM: A retrospective study (IISR-2021-200085) was conducted to evaluate the efficiency and safety of lanadelumab in real-life practice in Russia. \u0000MATERIALS AND METHODS: In all, 16 patients with hereditary angioedema and C1 inhibitor deficiency were enrolled at the initiation of lanadelumab treatment. The patients were predominantly female (81%; 13/16). The average age of patients was 29.9 years; 19% (3/16) of the patients were adolescents. The effectiveness was evaluated by comparing the patient-reported attack rates. The following PROs for the adults only were assessed initially and during the treatment: angioedema activity score, angioedema control test (AECT), angioedema quality of life questionnaire (AE-QoL), and hereditary angioedema activity score. The incidences of adverse events were evaluated. \u0000RESULTS: Before lanadelumab, 69% (11/16) of the patients received alternative long-term prophylaxis, which was canceled after the start of lanadelumab treatment. The average number of attacks per month and treated attacks per month prelanadelumab were 10 and 4.7 per patient, respectively. After 6 months of treatment, these values were 0.26 and 0.09, respectively (10 patients were symptom free at 6 months after the initiation of the treatment). After 3 months of treatment, the mean AECT values improved from 5.6 to 14.2 (p 0.001), and all patients showed adequate disease control. After 6 months of treatment, AE-QoL decreased from 58 to 19 (p 0.001). No serious adverse events related to lanadelumab were observed. \u0000CONCLUSION: Our study demonstrated that the composite effect of lanadelumab minimizes the attack rate and improves the quality of life in patients with hereditary angioedema. A good safety profile of lanadelumab is shown.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129906101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Etiological diagnosis of acute drug contact allergic reaction occurred during ophthalmic surgery","authors":"I. Vorzheva, Irina V. Barachtenko","doi":"10.36691/rja7527","DOIUrl":"https://doi.org/10.36691/rja7527","url":null,"abstract":"Drug allergy is one of the most common problems in clinical medicine including ophthalmology. The frequency and severity of drug-induced eye lesions continuously increase as the arsenal of active drugs increases. \u0000Among the common causes of eye contact allergy, along with traditionally noted antibiotics and anesthetics, an expanded list of the most remarkable drug allergens, including mydriatics (tropicamide and phenylephrine), beta blockers, dorzolamide, latanoprost, and topical corticosteroids, have been registered recently. In addition to active ingredients, ophthalmic preparations contain various auxiliary substances, such as benzalkonium chloride, chlorhexidine, and thiomersal, which possess sensitizing properties. \u0000This study presents a clinical case of a patient suffering from cataracts who developed an acute local allergic reaction during the introductory period of lens replacement surgery, resulting in the cancelation of surgical intervention. In addition, several drugs are used simultaneously, each of which can cause allergies and excipients in their composition. Approaches to specific diagnostics including the choice of skin tests are described depending on the clinical phenotype of drug allergy. After determining the cause of allergy, recommendations are given to the patient and ophthalmologist for further treatment, enabling the subsequent performance of the operation without complications.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123191214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to fit an antihistamine, taking into account the individual characteristics of the patient: From pharmacokinetics to profiling","authors":"N. Nenasheva, O. V. Sebekina, M. Peredelskaya, K. Akmalova","doi":"10.36691/rja12071","DOIUrl":"https://doi.org/10.36691/rja12071","url":null,"abstract":"The authors of the article describe the dependence of the effectiveness of any drug on the \"correctness\" of its choice for the patient and conclude that patient profiling can serve as an effective clinical method for selecting optimal therapy. When prescribing antihistamines, it is suggested to use the following main patient profiles: children, working adults, elderly patients. Each profile has its own specific purpose. \u0000The article presents own clinical experience of using fexofenadine based on patient profiling. Cases of fexofenadine therapy in patients with allergic rhinitis and chronic urticaria are given as specific examples. Fexofenadine has an optimal safety profile with minimal impact on concentration and cognitive abilities. In this regard, it can be recommended to employees whose activities are associated with the speed of psychomotor reactions, schoolchildren and university students, elderly patients with high drug load and comorbidity. \u0000The article discusses approaches to choosing the optimal second-generation antihistamine in patients of these groups seeking primary medical care when symptoms of urticaria and allergic rhinitis occur.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129181056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myoferline gene mutation сan be associated with recurrent angioedema","authors":"D. Fomina, S. Serdotetskova, E. Bobrikova, Julia G. Alekseeva, A. Roppelt, M. Lysenko","doi":"10.36691/rja12070","DOIUrl":"https://doi.org/10.36691/rja12070","url":null,"abstract":"Hereditary angioedema is a rare genetically determined disease characterized by the recurrent angioedema of various localizations with no response to systemic glucocorticosteroids, antihistamines. \u0000In the majority of hereditary angioedema cases C1-inhibitor level or its functional activity is decreased due to a mutation in the SERPING1 gene. In recent years, the expansion of genetic diagnostic recourses significantly changed our understanding of the pathogenesis of hereditary angioedema without of C1-inhibitor deficiency with previously unknown mutations. Currently mutations in six different genes have been identified as causing hereditary angioedema: factor XII (F12), plasminogen (PLG), angiopoietin 1 (ANGPT1), Kininogen 1 (KNG1), Myoferlin (MYOF), and heparan sulfate (HS)-glucosamine 3-O-sulfotransferase 6 (HS3ST6). Moreover, the last 3 of them are referred to a separate phenotype ― intrinsic endothelial dysfunction. \u0000In 2020 a series of clinical cases in patients with MYOF gene mutation in an Italian family were published. This type is exceptionally rare ― only 3 female relatives from the same family are described. \u0000This article presents a review of the actual international literature and describes the first clinical case of a male patient with a mutation in the myoferlin gene confirmed by genetic testing.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132876696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Janus kinase inhibitors efficacy for the treatment of adult atopic dermatitis in real clinical practice","authors":"E. Shatokhina, A. S. Polonskaia, A. Syryseva, A. Michenko, M. Shatokhin, L. S. Kruglova","doi":"10.36691/rja11544","DOIUrl":"https://doi.org/10.36691/rja11544","url":null,"abstract":"Atopic dermatitis is a common chronic dermatosis characterized by a wide variability of endotypes and phenotypes. \u0000Approaches to the treatment of atopic dermatitis are currently undergoing significant changes, especially in patients with moderate and severe forms of atopic dermatitis. JAK inhibitors according to the results of numerous studies have shown their efficacy in the treatment of various immune-mediated dermatological diseases such as atopic dermatitis, vitiligo, focal alopecia and psoriasis, etc. \u0000The article presents the experience of treating adult patients suffering from a severe form of atopic dermatitis with the selective JAK-1 inhibitor upadacitinib. The observations presented are of particular interest due to the fact that the patients were treated with upadacitinib monotherapy. It should be noted that the drug is highly effective against itching. No adverse events (including the development of infectious diseases, hematological disorders) were registered during dynamic observation (according to the results of laboratory studies).","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124044205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leukotriene receptor antagonists in the treatment of bronchial asthma \u0000[Consensus agreement \"Bronchial Asthma and LEukoTriene receptor antagonists (BALET)\"]","authors":"N. Ilyina, S. Avdeev, N. Geppe, I. Demko, A. Zhestkov, O. V. Zaitseva, E. Kondyurina, I. V. Kukes, O. Kurbacheva, A. B. Malakhov, Yury L. Mizernitsky, N. Nenasheva, A. Pampura, V. Revyakina","doi":"10.36691/rja7530","DOIUrl":"https://doi.org/10.36691/rja7530","url":null,"abstract":"Under the auspices of the Russian Association of Allergists and Clinical Immunologists and the Russian Pediatric Respiratory Society, an expert meeting \"Leukotriene receptor antagonists in the treatment of bronchial asthma\" was held. Asthma is a common non-communicable chronic disorder of the airways and is characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation. The creation and widespread use of inhaled corticosteroids (ICS) and other innovative classes of drugs for the treatment of bronchial asthma has significantly affected the ability to achieve control over the course of the disease. Despite this, in most European countries, more than half of patients with bronchial asthma have suboptimal disease control [1]. In the past decades, a class of leukotriene receptor blockers which contributes to the suppression of chronic allergic inflammation in patients with asthma has been actively studied. The majority of studies confirm the usefulness of montelukast as monotherapy and add-on therapy to ICS in mild to moderate asthma across all age groups [12-19,21-40]. However, experts note that in practical medicine the healthcare providers continue to ask questions regarding the effectiveness and safety of this class of medicines in patients with bronchial asthma. In this consensus document, the experts considered it important to provide an unequivocal answer for clinical practice to several topical questions regarding the use of antileukotriene therapy.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122639649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bioequivalence Study of Allergostin® Compared to Administration of Kestin® in Healthy Volunteers","authors":"E. Talikova","doi":"10.36691/rja7525","DOIUrl":"https://doi.org/10.36691/rja7525","url":null,"abstract":"Relevance. International non-proprietary name (INN) Ebastin is widely used in medical practice in the treatment of urticaria and allergic rhinitis. It is an antiallergic drug, which belongs to the second generation of H1-histamine receptor blocker, it is necessary to emphasize that Ebastin is effective when taken orally. As part of the registration of trade name Allergostin, a clinical study of its bioequivalence with Kestin was conducted with the participation of 26 healthy volunteers. \u0000Aim. The aim of this publication is summarize results of the clinical study of the comparative pharmacokinetics and bioequivalence, safety and tolerability of Allergostin, film-coated tablets, 20 mg (NTFF POLYSAN LLC, Russia), and Kestin, film-coated tablets, 20 mg (Almiral S.A., Spain), in healthy volunteers after a single oral dose on an empty stomach. \u0000Materials and methods. To confirm bioequivalence, an open, randomized, two-period, cross-over study of comparative pharmacokinetics and bioequivalence of drugs with a single oral intake on an empty stomach in adult healthy male and female volunteers was conducted. During the study, blood plasma samples were taken from volunteers. Each sample was tested by using a validated high performance liquid chromatography with tandem mass spectrometry method, the concentrations of ebastine and the active metabolite carabastin were determined. Based on obtained data , pharmacokinetic and statistical analysis was carried out, 90% confidence intervals (CI) were calculated for the ratio of the geometric mean values of the pharmacokinetic parameters Cmax and AUC0-72 for carabastin. \u0000Results. Based on results of statistical analysis, it was shown that the pharmacokinetic parameters of the test (Allergostin) and reference (Kestin) drug are characterized by high similarity. For the estimated pharmacokinetic parameters of carabastin, 90% CI ranged from 80-125% for AUC0-t and Cmax. \u0000Conclusion. Thus, according to the applied criteria, the drugs are recognized as bioequivalent.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131298398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Searching for predictive biomarkers of allergen-specific immunotherapy efficacy based on modern concepts of its mechanisms","authors":"D. Timoshenko, K. Pavlova, O. Kurbacheva","doi":"10.36691/rja7526","DOIUrl":"https://doi.org/10.36691/rja7526","url":null,"abstract":"Allergen-specific immunotherapy is the main pathogenetically substantiated method for the treatment of allergic diseases. It not only leads to a decrease in the clinical symptoms severity, but also has a disease-modifying effect, prevents the progression of the disease, prevents the development of asthma and the spreading of sensitization. Immunological tolerance driven by the allergen-specific immunotherapy is mediated by a complex interaction between various cells of innate and adaptive immunity. Despite the fact that the main mechanisms of allergen-specific immunotherapy have been described to date, the understanding of these processes becomes more detailed at the cellular, molecular and epigenetic levels every year. In turn, a deep understanding of the mechanisms underlying the developing and maintenance of tolerance to allergens during allergen-specific immunotherapy can help reveal predictive biomarkers of efficacy. These biomarkers could streamline the selection of patients by identifying the responders to allergen-specific immunotherapy. This review represents current concepts of the allergen-specific immunotherapy mechanism on various stages of the allergic process. Furthermore, supposed predictive biomarkers of the efficacy are described, taking into account promising directions of research in this area.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121157207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CLINICAL, FUNCTIONAL AND IMMUNOLOGICAL CHARACTERISTICS OF SEVERE BRONCHIAL ASTHMA","authors":"A. Kraposhina, I. Demko, Elena A. Sobkio","doi":"10.36691/rja6395","DOIUrl":"https://doi.org/10.36691/rja6395","url":null,"abstract":"Bronchial asthma is the most common and socially significant disease in humans. Among patients who cannot achieve control, a special group is patients with severe asthma. Objective: comprehensive assessment of clinical, functional, immunological features and pharmacotherapy of severe bronchial asthma in real clinical practice to optimize basic pathogenetic therapy. Materials and methods: 83 patients diagnosed with severe asthma were examined. Patients with severe asthma are divided into 2 groups: patients with and without fixed airway obstruction. Plasma concentrations of cytokines IL-4, IL-5, IL-9, IL-13, periostin, cathepsin S, TGF- were determined by solid-phase enzyme immunoassay. Immune status was investigated on the NAVIOS Flow Cytometer. Results: In both groups of severe bronchial asthma, we found a decrease in T helper and immunoregulatory index levels with simultaneous increases in cytotoxic T lymphocytes, natural T killers, naive T lymphocytes, activated T and B lymphocytes, and phagocytic index compared to controls. There were no differences in immune status between the groups and the resulting changes were independent of the presence or absence of fixed obstruction. In both study groups, we found an increase in cathepsin S and TGF- in plasma compared to control. We identified the most significant risk factors for the formation of fixed obstruction: taking SABA more than 4 inhalations per day (OR = 4.2) and FeNO concentration more than 20 ppb (OR = 6.0). There was a significant improvement in the clinical condition of patients with severe asthma with fixed obstruction while taking genetically engineered biological therapy for a year. Conclusion: To date, there is no unambiguous idea of the mechanisms of implementation of pathobiochemical reactions in the bronchial wall in severe asthma, which lead to the development of fixed airway obstruction. Severe asthma is variable and depends on the correct choice of management tactics.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128336098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Acarizax® drug solution to perform skin prick tests to confirm patient sensitization to house dust mites.","authors":"E. Nazarova, Anastasia S. Primak","doi":"10.36691/rja3911","DOIUrl":"https://doi.org/10.36691/rja3911","url":null,"abstract":"Objective: To assess the possibility of using a drug solution of Acarizax containing Derm house dust allergens. pteronyssinus and Derm. farinae in equal amounts - 12 SQ-HDM, in order to conduct skin prick tests to confirm the sensitization of patients to ODP.Methods: Skin prick tests with dilutions 1 tablet per 2.5 and 5 ml diluting liquid of the study drug with positive and negative controls. Statistical data processing was carried out using the Statistica 13.3 or IBM SPSS 17.0 software package. To analyze efficacy and safety data, standard parametric tests were used: Student's t-test for dependent/independent samples, analysis of variance (ANOVA) for repeated measurements, Mann-Whitney U-test, Shapiro-Wilk test. The analysis of AEs was planned to be based on an estimate of the frequency of AEs/serious AEs.Results: The correlation between the total level of specific IgE to tick allergens Derm was assessed. pteronyssinus and Derm. farinae measured at screening and papule size 20 minutes after application of the drug at a dilution of 1 tablet per 2.5 ml and 5 ml of diluting liquid - the correlation coefficient (r) in both groups (general) was 0.735 (high correlation), and 0.762 (high correlation) respectively. The result is statistically significant (p0.05) in both groups. A clinical trial has shown that the drug Acarizax, containing house dust allergens Derm. pteronyssinus and Derm.s farinae in equal amounts - 12 SQ-HDM, when used for the purpose of skin prick tests to confirm the sensitization of patients to ODP, is a safe and informative method.Conclusions: In order to conduct skin prick tests to confirm the sensitization of patients to ODP, the study drug can be used in a larger dilution - 1 tablet per 5 ml of diluting liquid. Acarizax medicinal product containing house dust allergens Derm. pteronyssinus and Derm. farinae in equal amounts - 12 SQ-HDM, when used for skin prick tests, is informative and well tolerated by patients.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"295 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121829927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}